Daniel J Starks bought $927k of ABT
director at ABBOTT LABORATORIES. 10,000 shares at an average of $92.65, traded Apr 27, 2026, filed Apr 28, 2026.
Score components
- +15RoleDirector
- +24Trade size$927k at market
- -5Relative to holdingsUnder 1% of holdings (0.1%)
- +18Price context2% above the 52-week low; 31% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -8.1%, 3m +15.1%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902132-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 24, 2026 | AGrant or award Common shares without par value | +2,286 | $0.00 | $0 | 6,741,103 | Apr 28, 2026 |
| Apr 27, 2026 | POpen-market purchase Common shares without par value | +10,000 | $92.65 | $927k | 6,751,103 | Apr 28, 2026 |
| Apr 24, 2026 | AGrant or award Option (right to buy)derivative | +7,105 | $0.00 | $0 | 7,105 | Apr 28, 2026 |
Related signals
Other insiders at ABBOTT LABORATORIES and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | ABBOTT LABORATORIES | John A. McCoy Jr. VICE PRESIDENT AND CONTROLLER | $2,958 27 shares | -0% | |
| 70Notable | ABBOTT LABORATORIES | Robert B Ford CHAIRMAN AND CEO | $46M 398,832 shares | -57% | |
| 43Moderate | ABBOTT LABORATORIES | Louis H. Morrone EXECUTIVE VICE PRESIDENT | $643k 5,850 shares | -8% | |
| 62Notable | ABBOTT LABORATORIES | John G Stratton director | $174k 2,000 shares | +9% | |
| 75Notable | ABBOTT LABORATORIES | Philip P Boudreau EVP AND CFO | $201k 2,200 shares | - | |
| 40Moderate | ABBOTT LABORATORIES | Daniel Gesua Sive Salvadori EVP AND GROUP PRESIDENT | $102k 885 shares | -1% | |
| 48Moderate | ABBOTT LABORATORIES | John A. McCoy Jr. VICE PRESIDENT AND CONTROLLER | $68k 585 shares | -2% | |
| 48Moderate | ABBOTT LABORATORIES | Mary K Moreland EXECUTIVE VICE PRESIDENT | $71k 613 shares | -1% | |
| 51Moderate | ABBOTT LABORATORIES | Louis H. Morrone EXECUTIVE VICE PRESIDENT | $132k 1,144 shares | -1% | |
| 39Weak | ABBOTT LABORATORIES | Eric Shroff Senior Vice President | $82k 709 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.